We previously analyzed the clinical implications of ASXL1 mutation in a large cohort of patients and found that this mutation occurred in 10.8% (54/501) of de novo AML patients and predicted a shorter survival [10]. The gene discussed is ASXL1; the disease is acute myeloid leukemia.